Bairbre Hickie

Bairbre Hickie is a prominent figure in the pharmaceutical industry, currently serving as the Senior Director and Franchise Head for Hereditary Angioedema (HAE) in Europe and Canada at Takeda. She has a strong background in commercial marketing and a solid scientific foundation, which she has leveraged throughout her extensive career in both affiliate and global capacities within the sector.

Education and Qualifications

Bairbre has pursued a diverse educational path that includes:

• Professional Diploma in Pharmaceutical Business Management from UCD Michael Smurfit Business School.
• Registered General Nurse certification from Beaumont Hospital School of Nursing.
• Higher Diploma in Nursing Studies, specializing in Intensive Care, from the Royal College of Surgeons/Beaumont Hospital.
• Post Graduate Diploma in Marketing and Management from Dublin Institute of Technology.

Career Overview

Bairbre's career at Takeda has been marked by several key roles:

• Franchise Head (ad interim) for HAE in Europe & Canada.
• Director of Launch Excellence Lead for Rare Disease in Europe & Canada.
• Business Operations Lead for the Plasma-derived Therapies Business Unit in Europe & Canada.
• Global Portfolio Lead in Market Development and Patient Value & Product Strategy within the Hematology Franchise at Shire before its acquisition by Takeda.

Prior to her tenure at Takeda, she held various significant positions at Fresenius Kabi, including Interim General Manager and Marketing Manager. Her career began as a Staff Nurse in the Intensive Care Unit at Beaumont Hospital.

Professional Impact

Bairbre Hickie is recognized for her ability to lead interdisciplinary teams effectively, driving success across various therapeutic areas such as Rare Diseases, Oncology, and Gastroenterology. Her commitment to continuous learning and professional development is evident through her diverse qualifications and roles across the pharmaceutical landscape.

Overall, Bairbre Hickie's extensive experience and leadership capabilities position her as a key player in advancing treatments for hereditary angioedema and other rare diseases within the pharmaceutical industry.